SHINE Technologies Secures $240M, Propelling Fusion and Medical Isotopes Forward
February 27, 2026, 3:49 pm
SHINE Medical Technologies
Location: United States
Employees: 201-500
Founded date: 2010
Total raised: $240M
SHINE Technologies secured $240 million in new equity funding, pushing its total capital raised beyond $1 billion. Dr. Patrick Soon-Shiong, a noted biotech visionary, joined its Board of Directors. This substantial investment will vigorously accelerate the company's pioneering work in commercial fusion technology, significantly expand its vital medical isotope production for advanced cancer therapies, and rapidly advance its innovative nuclear waste recycling solutions. The strategic infusion of capital profoundly strengthens SHINE's mission to deliver transformative healthcare, establish sustainable energy sources, and ultimately achieve commercial fusion power for global benefit.
SHINE Technologies recently announced a monumental financial milestone. The company closed a $240 million equity funding round. This latest injection of capital elevates SHINE's total funding past the $1 billion mark. It solidifies investor confidence in its commercially driven approach. This significant raise positions SHINE for rapid expansion.
The funding round saw strong participation. NantWorks led the investment. Fidelity Management & Research Company also joined. Sumitomo Corporation of Americas contributed. Pelican Energy Partners, Deerfield Management, and Oaktree Capital Management added support. Other existing investors reaffirmed their commitment. This diverse syndicate underscores broad belief in SHINE's vision.
Alongside the funding, a pivotal leadership appointment was made. Dr. Patrick Soon-Shiong, M.D., now sits on SHINE's Board of Directors. Dr. Soon-Shiong is Executive Chairman of ImmunityBio. He founded NantWorks. His extensive background in biotechnology and medicine brings invaluable strategic insight. His presence marks a significant moment for the company.
The capital will fuel multiple critical initiatives. SHINE plans to bolster its commercial fusion technology. This spans its existing product portfolio and services. Neutron testing remains a key application. It serves mission-critical components. Defense and aerospace industries rely on this precision.
Medical isotope production is another core focus. The funding will expand SHINE’s capabilities here. These radioisotopes are vital. They are used in targeted cancer therapies. They also aid diagnostic imaging procedures. This directly impacts global healthcare outcomes.
A strategic partnership was forged with NantWorks. It accompanied Dr. Soon-Shiong's investment. This agreement ensures priority access to Lu-177 supply from SHINE. Lutetium-177 is a crucial radioisotope. It is integral to next-generation targeted cancer treatments. This collaboration will accelerate therapeutic development. It links advanced fusion technology with critical medical needs.
SHINE Technologies is headquartered in Janesville, Wisconsin. The company focuses on fusion-based technology. Its development prioritizes safety, cost-efficiency, and environmental responsibility. SHINE has already commercialized fusion applications. Its neutron radiography provides detailed material analysis. Radiation-effects testing is vital for robust designs. Fusion materials research advances future energy solutions.
The company has also scaled its proprietary medical isotope production. It supplies high-quality radioisotopes globally. These are essential for diagnosing heart disease. They also support cancer diagnosis and therapy. SHINE operates one of North America's largest Lu-177 facilities. This facility boasts an annual capacity of up to 100,000 doses. It can readily scale to 200,000 doses per year.
SHINE’s Ilumira product demonstrates operational excellence. It has shipped to customers in 19 countries. Its reach spans four continents. Since its commercial launch in 2024, delivery has been exemplary. The product consistently achieves greater than 95% on-time, in-full delivery. This reliability is crucial for medical supply chains.
Beyond current commercial success, SHINE pursues transformative long-term goals. The company is developing nuclear waste recycling technology. This aims to support more sustainable nuclear energy. It addresses a significant environmental challenge. Converting waste into usable resources promises a cleaner future.
SHINE’s ultimate ambition is the commercialization of fusion energy. This represents a clean, virtually limitless power source. The company models its strategy on successful deep-tech industries. It involves incremental commercialization steps. Each stage builds capability and generates revenue. This methodical approach de-risks the path to fusion power.
The recent funding and strategic appointments underscore SHINE's impactful trajectory. It is advancing technology across multiple sectors. Healthcare benefits from improved cancer diagnostics and therapies. Sustainable energy solutions emerge from nuclear waste recycling. The promise of clean fusion power drives its long-term vision. SHINE Technologies continues to reshape global energy and medical landscapes. Its innovative spirit addresses some of humanity's greatest challenges.
SHINE Technologies recently announced a monumental financial milestone. The company closed a $240 million equity funding round. This latest injection of capital elevates SHINE's total funding past the $1 billion mark. It solidifies investor confidence in its commercially driven approach. This significant raise positions SHINE for rapid expansion.
The funding round saw strong participation. NantWorks led the investment. Fidelity Management & Research Company also joined. Sumitomo Corporation of Americas contributed. Pelican Energy Partners, Deerfield Management, and Oaktree Capital Management added support. Other existing investors reaffirmed their commitment. This diverse syndicate underscores broad belief in SHINE's vision.
Alongside the funding, a pivotal leadership appointment was made. Dr. Patrick Soon-Shiong, M.D., now sits on SHINE's Board of Directors. Dr. Soon-Shiong is Executive Chairman of ImmunityBio. He founded NantWorks. His extensive background in biotechnology and medicine brings invaluable strategic insight. His presence marks a significant moment for the company.
The capital will fuel multiple critical initiatives. SHINE plans to bolster its commercial fusion technology. This spans its existing product portfolio and services. Neutron testing remains a key application. It serves mission-critical components. Defense and aerospace industries rely on this precision.
Medical isotope production is another core focus. The funding will expand SHINE’s capabilities here. These radioisotopes are vital. They are used in targeted cancer therapies. They also aid diagnostic imaging procedures. This directly impacts global healthcare outcomes.
A strategic partnership was forged with NantWorks. It accompanied Dr. Soon-Shiong's investment. This agreement ensures priority access to Lu-177 supply from SHINE. Lutetium-177 is a crucial radioisotope. It is integral to next-generation targeted cancer treatments. This collaboration will accelerate therapeutic development. It links advanced fusion technology with critical medical needs.
SHINE Technologies is headquartered in Janesville, Wisconsin. The company focuses on fusion-based technology. Its development prioritizes safety, cost-efficiency, and environmental responsibility. SHINE has already commercialized fusion applications. Its neutron radiography provides detailed material analysis. Radiation-effects testing is vital for robust designs. Fusion materials research advances future energy solutions.
The company has also scaled its proprietary medical isotope production. It supplies high-quality radioisotopes globally. These are essential for diagnosing heart disease. They also support cancer diagnosis and therapy. SHINE operates one of North America's largest Lu-177 facilities. This facility boasts an annual capacity of up to 100,000 doses. It can readily scale to 200,000 doses per year.
SHINE’s Ilumira product demonstrates operational excellence. It has shipped to customers in 19 countries. Its reach spans four continents. Since its commercial launch in 2024, delivery has been exemplary. The product consistently achieves greater than 95% on-time, in-full delivery. This reliability is crucial for medical supply chains.
Beyond current commercial success, SHINE pursues transformative long-term goals. The company is developing nuclear waste recycling technology. This aims to support more sustainable nuclear energy. It addresses a significant environmental challenge. Converting waste into usable resources promises a cleaner future.
SHINE’s ultimate ambition is the commercialization of fusion energy. This represents a clean, virtually limitless power source. The company models its strategy on successful deep-tech industries. It involves incremental commercialization steps. Each stage builds capability and generates revenue. This methodical approach de-risks the path to fusion power.
The recent funding and strategic appointments underscore SHINE's impactful trajectory. It is advancing technology across multiple sectors. Healthcare benefits from improved cancer diagnostics and therapies. Sustainable energy solutions emerge from nuclear waste recycling. The promise of clean fusion power drives its long-term vision. SHINE Technologies continues to reshape global energy and medical landscapes. Its innovative spirit addresses some of humanity's greatest challenges.